{"nctId":"NCT00373425","briefTitle":"A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors","startDateStruct":{"date":"2006-09"},"conditions":["Non-small Cell Lung Cancer"],"count":1252,"armGroups":[{"label":"Erlotinib","type":"EXPERIMENTAL","interventionNames":["Drug: Erlotinib"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Erlotinib","otherNames":["OSI-774","Tarceva"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Primary tissue from patient's surgery must be epidermal growth factor receptor (EGFR)-positive by certain tests\n* Patients may have up to 4 cycles of chemotherapy after surgery\n* Complete removal of the tumor by surgery\n* Able to start drug under the following timelines:\n\n  * 6 months from the day of surgery for patients who get chemotherapy\n  * 3 months from the day of surgery for those who do not get chemotherapy\n* Confirmed diagnosis of Stage IB-IIIA NSCLC\n* Patients must be accessible for follow-up visits\n\nExclusion Criteria:\n\n* History of prior radiotherapy for NSCLC either before or after surgery\n* History of heart disease or uncontrolled heart arrhythmias within the previous year\n* History of poorly controlled gastrointestinal (GI) disorders that could affect the absorption of study drug\n* History of other cancer except certain skin or cervical cancers, patients who have had other cancer are eligible if they have remained disease free for at least 5 years\n* Patients who have received chemotherapy for NSCLC before surgery\n* Tumors with mixed histology of NSCLC and Small Cell Lung Cancer (SCLC). Patients with carcinoid tumors are not eligible.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Free Survival (DFS)","description":"DFS is the time from the date of randomization until the first day non-small cell lung cancer (NSCLC) relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"48.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival was defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival was defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival in Participants With EGFR Mutation - Positive Tumors","description":"Disease-free survival (DFS) is the time from the date of randomization until the first day NSCLC relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date. Activating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null},{"groupId":"OG001","value":"28.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival in Participants With EGFR Mutation - Positive Tumors","description":"Disease-free survival (DFS) is the time from the date of randomization until the first day NSCLC relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date. Activating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null},{"groupId":"OG001","value":"28.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Disease Free Survival (DFS)","description":"DFS is the time from the date of randomization until the first day that non-small cell lung cancer (NSCLC) relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"56.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Participants With EGFR Mutation - Positive Tumors","description":"Overall survival is defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.\n\nActivating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Participants With EGFR Mutation - Positive Tumors","description":"Overall survival is defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.\n\nActivating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a study participant and did not necessarily have a causal relationship with study treatment.\n\nAn AE was considered serious if it resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant, other important medical events, or is on the Astellas Always Serious List.\n\nA drug-related AE was any AE with at least a possible relationship to study treatment as assessed by the investigator. Severity was graded by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v3.0, where Grade 1=Mild AE; Grade=2 Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling; Grade 5=Death related to AE. AEs leading to death include deaths that occurred more than 30 days after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"599","spread":null},{"groupId":"OG001","value":"307","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"572","spread":null},{"groupId":"OG001","value":"181","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":118,"n":611},"commonTop":["Rash","Diarrhoea","Pruritus","Cough","Dry skin"]}}}